WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205979
CAS#: 459-86-9
Description: Mitoguazone is a guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
MedKoo Cat#: 205979
Name: Mitoguazone
CAS#: 459-86-9
Chemical Formula: C5H12N8
Exact Mass: 184.11849
Molecular Weight: 184.20238
Elemental Analysis: C, 32.60; H, 6.57; N, 60.83
Mitoguazone is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: Mitoguazone; MeGAG; methylG; methylGAG; MGBG; MGGH; DRG0223; NSC32946.
IUPAC/Chemical Name: (2E,2'E)-2,2'-(propane-1,2-diylidene)bis(hydrazinecarboximidamide)
InChi Key: MXWHMTNPTTVWDM-NXOFHUPFSA-N
InChi Code: InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+
SMILES Code: CC(/C=N/NC(N)=N)=N\NC(N)=N
The following data is based on the product molecular weight 184.20238 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Ferioli ME, Bottone MG, Soldani C, Pellicciari C. Administration of the antitumor drug mitoguazone protects normal thymocytes against spontaneous and etoposide-induced apoptosis. Cell Mol Life Sci. 2004 Nov;61(21):2767-73. PubMed PMID: 15549180.
2: Ferioli ME, Berselli D, Caimi S. Effect of mitoguazone on polyamine oxidase activity in rat liver. Toxicol Appl Pharmacol. 2004 Dec 1;201(2):105-11. PubMed PMID: 15541750.
3: Tulpule A, Espina BM, Pedro Santabarbara AB, Palmer M, Schiflett J, Boswell W, Smith S, Levine AM. Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Invest New Drugs. 2004 Jan;22(1):63-8. PubMed PMID: 14707495.
4: Ishmael DR, Chen WR, Hamilton SA, Liu H, Nordquist RE. A phase I human trial of mitoguazone and gemcitabine sequential bi-weekly treatment of cancer patients. Cancer Invest. 2003;21(4):542-9. PubMed PMID: 14533444.
5: Cheng CL, Lin EG, Chou CH. Rapid and sensitive quantitation of the antiproliferative agent mitoguazone in small volumes of plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 15;793(2):281-9. PubMed PMID: 12906902.
6: Ishmael DR, Chen WR, Nordquist JA, Liu H, Nordquist RE. Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors. Cancer Invest. 2003 Apr;21(2):217-26. PubMed PMID: 12743987.
7: Ferioli ME, Armanni A. Polyamine oxidase activity in rats treated with mitoguazone: specific and permanent decrease in thymus. Amino Acids. 2003;24(1-2):187-94. PubMed PMID: 12624752.
8: Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. Eur J Haematol Suppl. 2001 Jul;64:14-20. PubMed PMID: 11486395.
9: Wiernik PH, Gordon LI, Oken MM, Harris JE, O'Connell MJ. Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group. Leuk Lymphoma. 1999 Oct;35(3-4):375-7. PubMed PMID: 10706462.
10: Davidson K, Petit T, Izbicka E, Koester S, Von Hoff DD. Mitoguazone induces apoptosis via a p53-independent mechanism. Anticancer Drugs. 1998 Aug;9(7):635-40. PubMed PMID: 9773808.
